ACB vs CYTH
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Buy and CYTH is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACB’s FA Score shows that 0 FA rating(s) are green whileCYTH’s FA Score has 0 green FA rating(s).
- ACB’s FA Score: 0 green, 5 red.
- CYTH’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACB’s TA Score shows that 3 TA indicator(s) are bullish while CYTH’s TA Score has 4 bullish TA indicator(s).
- ACB’s TA Score: 3 bullish, 3 bearish.
- CYTH’s TA Score: 4 bullish, 5 bearish.
Price Growth
ACB (@Pharmaceuticals: Other) experienced а -1.29% price change this week, while CYTH (@Pharmaceuticals: Other) price change was -13.27% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.16%. For the same industry, the average monthly price growth was +2.97%, and the average quarterly price growth was -6.86%.
Reported Earning Dates
ACB is expected to report earnings on Jun 19, 2025.
CYTH is expected to report earnings on May 14, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (-2.16% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| ACB | CYTH | ACB / CYTH | |
| Capitalization | 239M | 39.1M | 611% |
| EBITDA | -1.64B | -20.03M | 8,173% |
| Gain YTD | -10.118 | 19.068 | -53% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 212M | 1.08M | 19,703% |
| Total Cash | 149M | 9.25M | 1,611% |
| Total Debt | 103M | 1.03M | 9,971% |
ACB | CYTH | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 59 | 25 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 91 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 100 | |
PRICE GROWTH RATING 1..100 | 87 | 53 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 11 | 28 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CYTH's Valuation (91) in the null industry is in the same range as ACB (94) in the Pharmaceuticals Other industry. This means that CYTH’s stock grew similarly to ACB’s over the last 12 months.
CYTH's Profit vs Risk Rating (100) in the null industry is in the same range as ACB (100) in the Pharmaceuticals Other industry. This means that CYTH’s stock grew similarly to ACB’s over the last 12 months.
ACB's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as CYTH (100) in the null industry. This means that ACB’s stock grew similarly to CYTH’s over the last 12 months.
CYTH's Price Growth Rating (53) in the null industry is somewhat better than the same rating for ACB (87) in the Pharmaceuticals Other industry. This means that CYTH’s stock grew somewhat faster than ACB’s over the last 12 months.
CYTH's P/E Growth Rating (100) in the null industry is in the same range as ACB (100) in the Pharmaceuticals Other industry. This means that CYTH’s stock grew similarly to ACB’s over the last 12 months.
| ACB | CYTH | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 88% | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 80% | 3 days ago 90% |
| Momentum ODDS (%) | 3 days ago 87% | 3 days ago 90% |
| MACD ODDS (%) | 3 days ago 90% | N/A |
| TrendWeek ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| TrendMonth ODDS (%) | 3 days ago 90% | 3 days ago 84% |
| Advances ODDS (%) | 29 days ago 76% | 8 days ago 83% |
| Declines ODDS (%) | N/A | 3 days ago 90% |
| BollingerBands ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| Aroon ODDS (%) | N/A | 3 days ago 90% |
CYTH and
Correlation & Price change
A.I.dvisor tells us that CYTH and ACB have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CYTH and ACB's prices will move in lockstep.
| Ticker / NAME | Correlation To CYTH | 1D Price Change % | ||
|---|---|---|---|---|
| CYTH | 100% | -9.44% | ||
| ACB - CYTH | 24% Poorly correlated | +3.24% | ||
| RDHL - CYTH | 24% Poorly correlated | -2.15% | ||
| TEVA - CYTH | 22% Poorly correlated | -3.78% | ||
| CGC - CYTH | 22% Poorly correlated | +3.45% | ||
| PTPI - CYTH | 21% Poorly correlated | -1.72% | ||
More | ||||